Kaynak M.S.Bogacz A.Stelmasi?ski M.Şahin S.2024-08-042024-08-0420111300-4182https://hdl.handle.net/11616/91196Amlodipine (AML), a third-generation dihydropiridin, is a long-acting L-calcium channel blocker used in the treatment of hypertension and angina pectoris. It exerts its effects by blocking the voltage-dependent L-calcium channels and binding to both dihydropiridin and nondihydropiridin binding sites. AML is well absorbed (96%) after oral administration and its bioavailability is between 64-90%. Its volume of distribution is about 16 to 21 L/kg and protein binding is 98% after oral administration. AML is extensively metabolized in the liver and its elimination from the plasma is biphasic with a terminal half-life of 30 to 50 h. It is excreted by renal route about 60%. According to Biopharmaceutics Classification System, AML is classified as class I drug by WHO. In this review physicochemical properties, pharmacology, analytical methods, pharmacokinetics and bioavailability of amlodipine are discussed.eninfo:eu-repo/semantics/closedAccessAmlodipineBioavailabilityBiopharmaceutics Classification System (BCS)PharmacokineticsReview Article3642072222-s2.0-84897432947Q3